These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28141698)

  • 1. Safety, Tolerability and Immunogenicity of Pentavalent Rotavirus Vaccine Manufactured by a Modified Process.
    Martinón-Torres F; Greenberg D; Varman M; Killar JA; Hille D; Strable EL; Stek JE; Kaplan SS
    Pediatr Infect Dis J; 2017 Apr; 36(4):417-422. PubMed ID: 28141698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
    Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS
    Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects.
    Lawrence J; He S; Martin J; Schödel F; Ciarlet M; Murray AV
    Hum Vaccin Immunother; 2014; 10(8):2247-54. PubMed ID: 25424929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.
    Levin MJ; Lindsey JC; Kaplan SS; Schimana W; Lawrence J; McNeal MM; Bwakura-Dangarembizi M; Ogwu A; Mpabalwani EM; Sato P; Siberry G; Nelson M; Hille D; Weinberg GA; Weinberg A
    AIDS; 2017 Jan; 31(1):49-59. PubMed ID: 27662551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of pentavalent rotavirus vaccine in Chinese infants.
    Mo Z; Ma X; Luo P; Mo Y; Kaplan SS; Shou Q; Zheng M; Hille DA; Arnold BA; ; Liao X
    Vaccine; 2019 Mar; 37(13):1836-1843. PubMed ID: 30808567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants.
    Tanaka Y; Yokokawa R; Rong HS; Kishino H; Stek JE; Nelson M; Lawrence J
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-7. PubMed ID: 28140752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
    Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
    Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentavalent rotavirus vaccine in infants with surgical gastrointestinal disease.
    McGrath EJ; Thomas R; Duggan C; Asmar BI
    J Pediatr Gastroenterol Nutr; 2014 Jul; 59(1):44-8. PubMed ID: 24614127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postdose 3 G1 serum neutralizing antibody as correlate of protection for pentavalent rotavirus vaccine.
    Liu GF; Hille D; Kaplan SS; Goveia MG
    Hum Vaccin Immunother; 2017 Oct; 13(10):2357-2363. PubMed ID: 28836489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.
    Shin S; Anh DD; Zaman K; Yunus M; Mai le TP; Thiem VD; Azim T; Victor JC; Dallas MJ; Steele AD; Neuzil KM; Ciarlet M
    Vaccine; 2012 Apr; 30 Suppl 1():A106-13. PubMed ID: 22520119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of the pentavalent rotavirus vaccine in African infants.
    Armah GE; Breiman RF; Tapia MD; Dallas MJ; Neuzil KM; Binka FN; Sow SO; Ojwando J; Ciarlet M; Steele AD
    Vaccine; 2012 Apr; 30 Suppl 1():A86-93. PubMed ID: 22520142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
    Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
    J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
    Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
    Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I clinical trial of a new 5-valent rotavirus vaccine.
    Luna EJ; Frazatti-Gallina NM; Timenetsky MC; Cardoso MR; Veras MA; Miraglia JL; Escobar AM; Grisi SJ; Raw I; Precioso AR
    Vaccine; 2013 Feb; 31(7):1100-5. PubMed ID: 23261048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea.
    Kim DS; Lee TJ; Kang JH; Kim JH; Lee JH; Ma SH; Kim SY; Kim HM; Shin SM
    Pediatr Infect Dis J; 2008 Feb; 27(2):177-8. PubMed ID: 18174862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
    Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
    Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation.
    Clark HF; Burke CJ; Volkin DB; Offit P; Ward RL; Bresee JS; Dennehy P; Gooch WM; Malacaman E; Matson D; Walter E; Watson B; Krah DL; Dallas MJ; Schödel F; Kaplan kM; Heaton P
    Pediatr Infect Dis J; 2003 Oct; 22(10):914-20. PubMed ID: 14551493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 °C for seven days.
    Kerdpanich A; Chokephaibulkit K; Watanaveeradej V; Vanprapar N; Simasathien S; Phavichitr N; Bock HL; Damaso S; Hutagalung Y; Han HH
    Hum Vaccin; 2011 Jan; 7(1):74-80. PubMed ID: 21228629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-Label Pilot Study to Compare the Safety and Immunogenicity of Pentavalent Rotavirus Vaccine (RV5) Administered on an Early Alternative Dosing Schedule with Those of RV5 Administered on the Recommended Standard Schedule.
    Saleh E; Eichner B; Clark DW; Gagliano ME; Troutman JM; Harrington L; McNeal M; Clements D
    J Pediatric Infect Dis Soc; 2018 Feb; 7(1):82-85. PubMed ID: 28340179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
    Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
    Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.